Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

Inclusion Criteria: * Age: less than or equal to 18 years of age. May be greater than 18 years of age if currently a St. Jude patient. * Patients with relapsed or refractory B-lineage ALL who are not eligible for hematopoietic stem cell transplantation (HSCT) because their leukemia is not in remission (\>5% blasts in bone marrow as evidenced either by morphology or by flow cytometry). * Shortening fraction greater than or equal to 25%. * Glomerular filtration rate greater than or equal to 50 cc/min/1.73 m2. * Pulse oximetry greater than or equal to 92% on room air. * Direct bilirubin less than or equal to 3.0 mg/dL. * Alanine aminotransferase (ALT) is no more than 2 times the upper limit of normal. * Aspartate transaminases (AST) is no more than 2 times the upper limit of normal. * Karnofsky or Lansky performance score of greater than or equal to 50. * No known allergy to murine products or HAMA testing results within normal limits. * No prior receipt of a gene-transfer agent (e.g. retroviral, adenoviral, lentiviral vector). * Does not have a current pleural or pericardial effusion. * Has a suitable adult family member donor available for NK cell donation. * Has recovered from all acute NCI Common Toxicity Criteria grade II-IV non-hematologic acute toxicities resulting from previous therapy as per the judgment of the principal investigator. * At least two weeks since receipt of any biological therapy, systemic chemotherapy, and/or radiation therapy. * Is not receiving more than the equivalent of prednisone 10 mg daily. Exclusion Criteria: * Pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment) * Breastfeeding